



US005767103A

United States Patent [19]
Greenberg et al.

[11] **Patent Number:** **5,767,103**
[45] **Date of Patent:** **Jun. 16, 1998**

- [54] **NITRIC OXIDE SEQUESTRANT**
- [75] **Inventors:** **Stanley S. Greenberg; Jianming Xie; Mark J. S. Miller**, all of New Orleans; **Judith Zatarian-Kuebel**, Mandeville, all of La.
- [73] **Assignee:** **Research Corporation Tech., Inc.**, Tucson, Ariz.
- [21] **Appl. No.:** **244,179**
- [22] **PCT Filed:** **May 17, 1994**
- [86] **PCT No.:** **PCT/US94/05650**
§ 371 Date: **Apr. 19, 1995**
§ 102(e) Date: **Apr. 19, 1995**
- [87] **PCT Pub. No.:** **WO95/31204**
PCT Pub. Date: **Nov. 23, 1995**
- [51] **Int. Cl.⁶** **A61K 31/70**
- [52] **U.S. Cl.** **514/52**
- [58] **Field of Search** **514/52**

[56] **References Cited**

U.S. PATENT DOCUMENTS

5,084,482 1/1992 Hirsch et al. 514/562
5,317,040 5/1994 Goldman 514/634
5,480,866 1/1996 Bonaventura et al. 514/6

FOREIGN PATENT DOCUMENTS

9054534 4/1990 Australia .
9169487 1/1991 Australia .

OTHER PUBLICATIONS

J.A. Lorente, et al. "L-arginine Pathway in the Sepsis Syndrome"; *Crit. Care Med.*; 21: 1287-1295 (1993).
C. Nathan "Nitric Oxide as a Secretory Product of mammalian Cells"; *FASEB*. 6: 3051-3064 (1992).

E. Nava, et al. "Inhibition of Nitric oxide Synthesis in Septic Shock: How Much is Beneficial?"; *Lancet*. 338: 1555-1556 (1991).

R.M.J. Palmer "Discovery of Nitric Oxide in the Vessel Wall". A. Unifying Concept in the Pathogenesis of Species *Arch. Surg.*, 128: 396-401 (1993).

S. Moncada, et al. "Mechanisms of Disease: The L-Arginine-Nitric Oxide Pathway" *New Eng. J.* 329: 2002-2012 (1993).

J. Zatarain, et al. "Vitamin B12A Prevents and Reverses Endotoxin-Mediated Hypotension and Decreases Mortality by Binding Excess Nitric Oxide" *FASEB*. 8: 2077 (1994).

M.A.S. Rajanayagam, et al., *British Journal of Pharmacology*. 108(1). pp. 3-5. 1993.

Primary Examiner—Raymond Henley, III
Attorney, Agent, or Firm—Scully, Scott, Murphy & Presser

[57] **ABSTRACT**

The present invention describes a method of sequestering nitric oxide from the bloodstream, endothelium or tissues of mammals by administering a cobalamin to such mammals. A method of treating diseases characterized by elevated nitric oxide levels in the bloodstream, endothelium or tissues is further provided. In particular, a method of treating sepsis by administering a therapeutic dose of hydroxocobalamin is described by the present invention. A method of alleviating systemic hypotension in a septic patient is further described by this invention. A pharmaceutical composition comprising a cobalamin in a concentration ranging from 0.5 to 50 mg composition/Kg body weight for mammals and is also provided.

16 Claims, 14 Drawing Sheets